

# 4CPS-089. COMPARATIVE EFFECTIVENESS OF NINTEDANIB PLUS DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN ADENOCARCINOMA NON-SMALL CELL LUNG CANCER

ATC code: L01 - Cytostatics

M. MERINO ALMANZAN<sup>1</sup>, J.M. DUARTE PEREZ<sup>2</sup>, J.F. MARIN POZO<sup>1</sup>, R. CLARAMUNT GARCIA<sup>1</sup>, C.L. MUÑOZ CID<sup>1</sup>, I. CABA PORRAS<sup>1</sup>  
<sup>1</sup>COMPLEJO HOSPITALARIO JAEN, HOSPITAL PHARMACY, JAÉN, SPAIN  
<sup>2</sup>UNIVERSITY OF GRANADA, PHARMACOLOGY, GRANADA, SPAIN

## BACKGROUND AND IMPORTANCE

Nintedanib is indicated in combination with docetaxel for the treatment of non-small cell lung cancer (nSCLC) with adenocarcinoma histology after failure to first-line chemotherapy.

## AIM AND OBJECTIVES

To evaluate the effectiveness of nintedanib in nSCLC, according to the conditions of use indicated in the data sheet and compare the health results obtained against a historical control of monotherapy treatment with docetaxel, real word data.

## MATERIAL AND METHODS

A retrospective observational study is designed, which includes all patients treated with docetaxel monotherapy (DOm) or nintedanib + docetaxel (Ni-DO) from January 2013 to December 2018 in 2nd or later line for nSCLC, in a reference hospital in oncology that covers a population of 600,000 inhabitants. The main variable is global survival (OS). Other variables are progression-free survival (PFS), duration of treatment (DT) and response, and demographic data of the patients. A Kaplan-Meier analysis and Cox regression is performed for dependent variables (OS and PFS) and frequency analysis, or with measures of central tendency and dispersion.

## RESULTS

### POPULATION

•55 patients (78,2% male): 21 Ni-DO, 34 DOm

Performance status: ECOG 0 (32,7%), ECOG 1(51,9%), ECOG 2(15,4%)

•71,1% smokers, 19,2% ex-smokers, 9,6% non-smokers.

DT in DOm: 2.5 months ( $\sigma=2.6$ ) and in DT Ni-DO: 5.2 months ( $\sigma=5.6$ );  $p=0.016$

•OS: 6.9 months in DOm and 8.3 months in Ni-DO;  $p=0.08$ . HR: 0.59 (IC95%: 0.33-1.07)

•SLP: 2.8 months in DOm and 4.7 months in Ni-DO;  $p=0.038$ . HR: 0.50 (IC95%: 0.26-0.98)

Partial Response: 22.7% and stabilization: 27.3%

## CONCLUSION AND RELEVANCE

In our geographic area we have not been able to find a significant difference in the effectiveness of Ni-DO versus DOm in terms of OS although PFS and DT of the treatments was significantly higher with Ni-DO arm.



<https://www.eahp.eu/25-4CPS-089>